|
1
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vinay DS and Kwon BS: Immunotherapy of
cancer with 4-1BB. Mol Cancer Ther. 11:1062–1070. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hodge JW, Greiner JW, Tsang KY, Sabzevari
H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL,
Panicali D, et al: Costimulatory molecules as adjuvants for
immunotherapy. Front Biosci. 11:788–803. 2006. View Article : Google Scholar
|
|
4
|
Cheuk AT, Mufti GJ and Guinn BA: Role of
4-1BB: 4-1BB ligand in cancer immunotherapy. Cancer Gene Ther.
11:215–226. 2004. View Article : Google Scholar
|
|
5
|
Laderach D, Movassagh M, Johnson A,
Mittler RS and Galy A: 4-1BB co-stimulation enhances human
CD8+ T cell priming by augmenting the proliferation and
survival of effector CD8+ T cells. Int Immunol.
14:1155–1167. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shuford WW, Klussman K, Tritchler DD, Loo
DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen
CP, et al: 4-1BB costimulatory signals preferentially induce
CD8+ T cell proliferation and lead to the amplification
in vivo of cytotoxic T cell responses. J Exp Med. 186:47–55. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cannons JL, Lau P, Ghumman B, DeBenedette
MA, Yagita H, Okumura K and Watts TH: 4-1BB ligand induces cell
division, sustains survival, and enhances effector function of CD4
and CD8 T cells with similar efficacy. J Immunol. 167:1313–1324.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cooper D, Bansal-Pakala P and Croft M:
4-1BB (CD137) controls the clonal expansion and survival of CD8 T
cells in vivo but does not contribute to the development of
cytotoxicity. Eur J Immunol. 32:521–529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee HW, Park SJ, Choi BK, Kim HH, Nam KO
and Kwon BS: 4-1BB promotes the survival of CD8+ T
lymphocytes by increasing expression of Bcl-xL and Bfl-1. J
Immunol. 169:4882–4888. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuroki M, Matsuo Y, Kinugasa T and
Matsuoka Y: Three different NCA species, CGM6/CD67, NCA-95, and
NCA-90 are comprised in the major 90 to 100 kDa band of granulocyte
NCA detectable upon SDS-polyacrylamide gel electrophoresis. Biochem
Biophys Res Comm. 182:501–506. 1992. View Article : Google Scholar
|
|
11
|
Scholzel S, Zimmermann W, Schwarzkopf G,
Grunert F, Rogaczewski B and Thompson J: Carcinoembryonic antigen
family members CEACAM6 and CEACAM7 are differentially expressed in
normal tissues and oppositely deregulated in hyperplastic
colorectal polyps and early adenomas. Am J Pathol. 157:1051–1052.
2000.
|
|
12
|
Kuroki M, Matsushita H, Matsumoto H,
Hirose Y, Senba T and Yamamoto T: Nonspecific cross-reacting
antigen 50/90 (NCA-50/90) as a new tumor marker. Anticancer Res.
19:5599–5606. 1999.
|
|
13
|
Hinoda Y, Saito T, Takahashi H, Itoh F,
Adachi M and Imai K: Induction of nonspecific cross-reacting
antigen mRNA by interferongamma and anti-fibronectin receptor
antibody in colon cancer cells. J Gastroenterol. 32:200–205. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blumenthal RD, Leon E, Hansen HJ and
Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in
primary and metastatic cancers. BMC Cancer. 7:22007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye JX, Zhang YT, Zhang XG, Ren DM and Chen
WC: Recombinant attenuated Salmonella harboring 4-1BB ligand gene
enhances cellular immunity. Vaccine. 27:1717–1723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan JX, Chen WC, Zhang XG and Zhang GB:
The change of immunoactivity of dendritic cells induced by
recombinant rat 4-1BBL. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
24:764–767. 2008.In Chinese. PubMed/NCBI
|
|
17
|
Kyriakos M: The President’s cancer, the
Dukes classification, and confusion. Arch Pathol Lab Med.
109:1063–1066. 1985.PubMed/NCBI
|
|
18
|
Kawai H, Ishii A, Washiya K, Konno T, Kon
H, Yamaya C, Ono I, Minamiya Y and Ogawa J: Estrogen receptor alpha
and beta are prognostic factors in non-small cell lung cancer. Clin
Cancer Res. 11:5084–5089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Watts TH: TNF/TNFR family members in
costimulation of T cell responses. Annu Rev Immunol. 23:23–68.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Croft M: Co-stimulatory members of the
TNFR family: keys to effective T-cell immunity? Nat Rev Immunol.
3:609–620. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim HY, Kim KK, Zhou FC, Yoon JW, Hill JM
and Kwon BS: 4-1BB-like molecule is expressed in islet-infiltrating
mono-nuclear cells and in the gray matter of the brain. Cell Biol
Int. 26:271–278. 2002. View Article : Google Scholar
|
|
22
|
Ye J, Li L, Zhang Y, Zhang X, Ren D and
Chen W: Recombinant salmonella-based 4-1BBL vaccine enhances T cell
immunity and inhibits the development of colorectal cancer in rats:
in vivo effects of vaccine containing 4-1BBL. J Biomed Sci.
20:82013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hou Y, Kavanagh B and Fong L: Distinct
CD8+ T cell repertoires primed with agonist and native
peptides derived from a tumor-associated antigen. J Immunol.
180:1526–1534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loisel-Meyer S, Felizardo T, Mariotti J,
Mossoba ME, Foley JE, Kammerer R, Mizue N, Keefe R, McCart JA and
Zimmermann W: Potent induction of B- and T-cell immunity against
human carcinoembryonic antigen-expressing tumors in human
carcinoembryonic antigen transgenic mice mediated by direct
lentivector injection. Mol Cancer Ther. 8:692–702. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hörig H, Medina FA, Conkright WA and
Kaufman HL: Strategies for cancer therapy using carcinoembryonic
antigen vaccines. Expert Rev Mol Med. 2:1–24. 2000.
|
|
26
|
Jantscheff P, Terracciano L, Lowy A,
Glatz-Krieger K, Grunert F, Micheel B, Brümmer J, Laffer U, Metzger
U, Herrmann R, Rochlitz C, et al: Expression of CEACAM6 in
resectable colorectal cancer: a factor of independent prognostic
significance. J Clin Oncol. 21:3638–3846. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beauchemin N and Arabzadeh A:
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs)
in cancer progression and metastasis. Cancer Metastasis Rev.
32:643–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maskens AP: Histogenesis and growth
pattern of 1, 2-dimethylhydrazine-induced rat colon adenocarcinoma.
Cancer Res. 36:1585–1592. 1976.PubMed/NCBI
|
|
29
|
Takagi S, Chen K, Schwarz R, Iwatsuki S,
Herberman RB and Whiteside TL: Functional and phenotypic analysis
of tumor-infiltrating lymphocytes isolated from human primary and
metastatic liver tumors and cultured in recombinant interleukin-2.
Cancer. 63:102–111. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B and Lagorce-Pages C: Type, density, and
location of immune cells within human colorectal tumors predict
clinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Curiel TJ: Regulatory T cells and
treatment of cancer. Curr Opin Immunol. 20:241–246. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schiavon V, Roth P, Bolton WE, Farcet JP,
Bensussan A and Boumsell L: Lymphocytes subsets in normal
individuals: analysis by four color immunofluorescence and flow
cytometry on whole blood. Tissue Antigens. 48:312–318. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sharma RK, Elpek KG, Yolcu ES, Schabowsky
RH, Zhao H, Bandura-Morgan L and Shirwan H: Costimulation as a
platform for the development of vaccines: a peptide-based vaccine
containing a novel form of 4-1BB ligand eradicates established
tumors. Cancer Res. 69:4319–4326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sharma RK, Schabowsky RH, Srivastava AK,
Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ,
Yolcu ES, et al: 4-1BB ligand as an effective multifunctional
immunomodulator and antigen delivery vehicle for the development of
therapeutic cancer vaccines. Cancer Res. 70:3945–3954. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Walzer T, Jaeger S, Chaix J and Vivier E:
Natural killer cells: from CD3−NKp46+ to
post-genomics meta-analyses. Curr Opin Immunol. 19:365–372. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Halama N, Braun M, Kahlert C, Spille A,
Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I,
Schirmacher P, et al: Natural killer cells are scarce in colorectal
carcinoma tissue despite high levels of chemokines and cytokines.
Clin Cancer Res. 17:678–689. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Ju S and Shu Y: Research on the
effects of CD137 signaling on the function of
CD3-CD56+NK cells. J Nanjing Medical University.
23:10–14. 2009. View Article : Google Scholar
|
|
38
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hiraoka N, Onozato K, Kosuge T and
Hirohashi S: Prevalence of FOXP3+ regulatory T cells
increases during the progression of pancreatic ductal
adenocarcinoma and its premalignant lesions. Clin Cancer Res.
12:5423–5434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kobayashi N, Hiraoka N, Yamagami W, Ojima
H, Kanai Y and Kosuge T: FOXP3+ regulatory T cells
affect the development and progression of hepatocarcinogenesis.
Clin Cancer Res. 13:902–911. 2007. View Article : Google Scholar : PubMed/NCBI
|
